{"id":"voriconazole-vfend","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Rash"},{"rate":"1-5%","effect":"Hypersensitivity reactions"},{"rate":"1-5%","effect":"Liver enzyme elevations"},{"rate":"1-5%","effect":"Renal impairment"}]},"_chembl":{"chemblId":"CHEMBL638","moleculeType":"Small molecule","molecularWeight":"349.32"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It achieves this by targeting the enzyme lanosterol 14α-demethylase, which is necessary for the conversion of lanosterol to ergosterol. This action disrupts the integrity of the fungal cell membrane, ultimately leading to cell death.","oneSentence":"Voriconazole is an antifungal medication that inhibits the synthesis of ergosterol, an essential component of fungal cell membranes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:54.947Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of invasive aspergillosis"},{"name":"Treatment of candidemia and other forms of invasive candidiasis"},{"name":"Treatment of serious fungal infections caused by Scedosporium apiospermum and Fusarium species"}]},"trialDetails":[{"nctId":"NCT05458102","phase":"PHASE1","title":"Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2022-08-19","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":18},{"nctId":"NCT06710600","phase":"NA","title":"Phototoxicity of Frequently Prescribed Medicines","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2022-09-22","conditions":"Phototoxicity","enrollment":12},{"nctId":"NCT06137690","phase":"","title":"Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients","status":"UNKNOWN","sponsor":"People's Hospital of Zhengzhou University","startDate":"2018-07-01","conditions":"Invasive Fungal Infection","enrollment":550},{"nctId":"NCT05655689","phase":"","title":"The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2021-12-31","conditions":"Bacterial Keratitis, Fungal Keratitis, Mixed Bacterial and Fungal Keratitis","enrollment":123},{"nctId":"NCT01782131","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-09-25","conditions":"Fungal Infections, Invasive Pulmonary Aspergillosis","enrollment":585},{"nctId":"NCT05380245","phase":"PHASE4","title":"Drug-Drug Interaction Study of Voriconazole With Clarithromycin.","status":"COMPLETED","sponsor":"Abdul Wali Khan University Mardan","startDate":"2018-11-01","conditions":"Healthy","enrollment":12},{"nctId":"NCT04004078","phase":"","title":"An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM","status":"COMPLETED","sponsor":"People's Hospital of Zhengzhou University","startDate":"2018-03-01","conditions":"Invasive Fungal Infection","enrollment":314},{"nctId":"NCT03121235","phase":"","title":"PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2017-04-20","conditions":"Aspergillosis, Invasive Pulmonary","enrollment":320},{"nctId":"NCT04229303","phase":"PHASE1","title":"Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2020-02-11","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":58},{"nctId":"NCT04966234","phase":"PHASE2, PHASE3","title":"A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection","status":"UNKNOWN","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2021-04-22","conditions":"Cystic Fibrosis, Aspergillosis","enrollment":135},{"nctId":"NCT02631954","phase":"PHASE1","title":"Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-09","conditions":"Aspergillus Infections, Candida Infections, Fungal Infections","enrollment":24},{"nctId":"NCT02689713","phase":"PHASE2","title":"Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent","status":"WITHDRAWN","sponsor":"Kenneth Hargreaves","startDate":"2018-06-15","conditions":"Pain, Thermal Injury, Burns","enrollment":""},{"nctId":"NCT03760276","phase":"PHASE1","title":"A Study to Evaluate the Appropriateness of the Voriconazole Dosing Regimen","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2018-08-20","conditions":"Fungal Infection","enrollment":11},{"nctId":"NCT00557362","phase":"PHASE1, PHASE2","title":"Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2007-11","conditions":"Fungal Keratitis","enrollment":120},{"nctId":"NCT00423163","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis","status":"WITHDRAWN","sponsor":"Astellas Pharma Inc","startDate":"2007-02","conditions":"Aspergillosis/Blood, Aspergillosis/Invasive","enrollment":""},{"nctId":"NCT01539330","phase":"PHASE4","title":"Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy","status":"COMPLETED","sponsor":"Martin-Luther-Universität Halle-Wittenberg","startDate":"2009-02","conditions":"Healthy","enrollment":9},{"nctId":"NCT01073631","phase":"","title":"Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® Tablet In Korea","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-03","conditions":"Serious Fungal Infections","enrollment":543},{"nctId":"NCT01073618","phase":"","title":"Non-Interventional Post Marketing Surveillance Study To Observe The Safety And Efficacy Of Vfend® IV","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-03","conditions":"Serious Fungal Infections","enrollment":692},{"nctId":"NCT01254708","phase":"PHASE2","title":"Safety and Efficacy Study of Inhaled AmBisome for Prevention of Aspergillus Colonization in Lung Transplant Recipients","status":"SUSPENDED","sponsor":"University Health Network, Toronto","startDate":"2012-01","conditions":"Lung Transplant Recipient","enrollment":4},{"nctId":"NCT01137292","phase":"","title":"Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-04","conditions":"Invasive Fungal Infections","enrollment":177},{"nctId":"NCT00163111","phase":"PHASE3","title":"A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.","status":"COMPLETED","sponsor":"Pfizer","startDate":"1998-09","conditions":"Candidiasis","enrollment":412},{"nctId":"NCT00386802","phase":"PHASE4","title":"Antifungal Use in Oncohematological Neutropenic Patients","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-08","conditions":"Invader Fungal Infection","enrollment":115},{"nctId":"NCT00150319","phase":"PHASE1, PHASE2","title":"An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend","status":"TERMINATED","sponsor":"Pfizer","startDate":"2005-06","conditions":"Kidney Failure","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vfend","UK-109,496; Vfend; voriconazole"],"phase":"phase_3","status":"active","brandName":"voriconazole (VFEND®)","genericName":"voriconazole (VFEND®)","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Voriconazole, also known as VFEND, is a small molecule inhibitor of the cytochrome P450 51 enzyme, specifically targeting lanosterol 14-alpha demethylase. It is used to treat various serious fungal infections, including invasive pulmonary aspergillosis, as indicated by clinical trials on ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2002-03-19T00:00:00.000Z","mah":"Pfizer Europe MA EEIG","brand_name_local":"Vfend","application_number":"EMEA/H/C/000387"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}